Licence extension for Januvia

1 October 2009

Januvia (sitagliptin) is now licensed for first-line treatment of type II diabetes when metformin is contraindicated or not tolerated. The recommended dose is 100mg once daily.

View Januvia drug record

Further information: Merck

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

The most up-to-date drug information at your fingertips.

  • Get the prescribing support you need.
  • Register today for full access to the MIMS database, plus tables and guideline summaries, new and deleted products and consultation tools.
Register Now
Already Registered?

Forgotten password?

More from MIMS

Male clinician in white coat showing female patient how to use IQoro device.

Training device for reflux and dysphagia available on NHS

A neuromuscular training device for patients with reflux-based...

Deleted products - live tracker

EXCLUSIVE TO SUBSCRIBERS See the latest products removed...

New and deleted indications - live tracker

EXCLUSIVE TO SUBSCRIBERS See the latest changes to...

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...